Sienna Biopharmaceuticals (SNNA) Announces Earnings Results, Misses Estimates By $0.03 EPS
Sienna Biopharmaceuticals (NASDAQ:SNNA) issued its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.03), MarketWatch Earnings reports.
NASDAQ SNNA traded down $0.52 during trading on Friday, reaching $10.05. 26,504 shares of the company’s stock were exchanged, compared to its average volume of 72,428. Sienna Biopharmaceuticals has a fifty-two week low of $8.77 and a fifty-two week high of $25.71. The firm has a market capitalization of $212.16 million, a PE ratio of -1.94 and a beta of 1.48. The company has a current ratio of 5.82, a quick ratio of 5.82 and a debt-to-equity ratio of 0.54.
A number of equities analysts recently weighed in on the company. BMO Capital Markets dropped their price target on Sienna Biopharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 1st. Zacks Investment Research cut Sienna Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
See Also: Preferred Stock
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.